{
    "clinical_study": {
        "@rank": "1415", 
        "arm_group": [
            {
                "arm_group_label": "A-B-C", 
                "arm_group_type": "Experimental", 
                "description": "Drug will be administered to according to A-B-C sequence for 3 period."
            }, 
            {
                "arm_group_label": "A-C-B", 
                "arm_group_type": "Experimental", 
                "description": "Drug will be administered to according to A-C-B sequence for 3 period."
            }, 
            {
                "arm_group_label": "B-C-A", 
                "arm_group_type": "Experimental", 
                "description": "Drug will be administered to according to B-C-A sequence for 3 period."
            }, 
            {
                "arm_group_label": "B-A-C", 
                "arm_group_type": "Experimental", 
                "description": "Drug will be administered to according to B-A-C sequence for 3 period."
            }, 
            {
                "arm_group_label": "C-A-B", 
                "arm_group_type": "Experimental", 
                "description": "Drug will be administered to according to C-A-B sequence for 3 period."
            }, 
            {
                "arm_group_label": "C-B-A", 
                "arm_group_type": "Experimental", 
                "description": "Drug will be administered to according to C-B-A sequence for 3 period."
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, open-label, six-sequence, three-period, three-treatment, multiple dosing\n      clinical trial to investigate the pharmacokinetic drug interaction between Pregabalin and\n      Thioctic acid after oral administration in healthy male volunteers."
        }, 
        "brief_title": "Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Body weight ae least 50kg and BMI(body mass index) within the range of 18 to 27kg/m2\n\n          2. Provision of signed written informed consent\n\n          3. Acceptable physical examination and clinical examination, during screening\n\n        Exclusion Criteria:\n\n          1. A subject with clinical evidence or history of hepatic (including carrier of\n             hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic,\n             hematologic, oncologic, psychiatric, or cardiovascular disease\n\n          2. A subject with a history of gastrointestinal disease or surgery (except simple\n             appendectomy or repair of hernia), which can influence the absorption of the study\n             drug\n\n          3. A subject with history of allergies including study drug (pregabalin or thioctic\n             acid) or other drug allergies (aspirin, antibiotics, etc.), or history of clinically\n             significant allergies\n\n          4. A subject whose lab test results are as follows: AST(SGOT), ALT(SGPT) > 1.5 x upper\n             limit of reference range\n\n          5. Presence or history of drug abuse or positive result in urine drug screening test\n\n          6. Use any prescriptive medication, Korean traditional medication not considered\n             acceptable by the clinical investigator during the last 14 days period before first\n             dosing, or use any OTC medication not considered acceptable by the clinical\n             investigator during the last 7 days period before first dosing (if used medication is\n             considered acceptable by investigator, patients can be included)\n\n          7. Participation in clinical trials of any drug within 60 days prior to the\n             participation of the study\n\n          8. Blood donation during 2 months or apheresis during 1 month before the study\n\n          9. Use of alcohol over 21 units/weeks\n\n         10. Smoker who smoke more than 10 cigarettes per day or who cannot stop smoking during\n             the study period (from 24 hours before hospitalization to discharge)\n\n         11. Use of caffeine drink during the study period(from 24 hours before hospitalization to\n             discharge)\n\n         12. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products\n             during the study\n\n         13. Judged to be inappropriate for the study by the investigator after reviewing clinical\n             laboratory results or other reasons."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 3, 2013", 
        "id_info": {
            "nct_id": "NCT01808300", 
            "org_study_id": "UMPT-1", 
            "secondary_id": "H-1212-030-449"
        }, 
        "intervention": {
            "arm_group_label": [
                "A-B-C", 
                "A-C-B", 
                "B-C-A", 
                "B-A-C", 
                "C-A-B", 
                "C-B-A"
            ], 
            "description": "A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days\nB: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days\nC: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B", 
            "intervention_name": "Pregabalin 300mg, Thioctic acid 600mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Thioctic Acid", 
                "Pregabalin", 
                "Gamma-Aminobutyric Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "lastchanged_date": "August 21, 2013", 
        "number_of_arms": "6", 
        "official_title": "A Randomized,Open-label,Six-sequence,Three-period,Three-treatment,Multiple Dosing Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid After Oral Administration in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Kyung-Sang Yu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea, Republic of: Korea Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "AUC\u03c4,ss / Cmax of pregabalin and thioctic acid", 
            "safety_issue": "No", 
            "time_frame": "2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Ctrough,ss / Tmax,ss / t\u00bd / CL/F of pregabalin and thioctic acid", 
            "safety_issue": "No", 
            "time_frame": "2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h"
        }, 
        "source": "Unimed Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Unimed Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}